Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAhmad AlabdulkarimACAdrian ChoyDADelphine Appadurai

Discussion

Loading...

Member takes

Overview

Cohort analysis reveals poor survival outcomes and highlights the need for better prognostic models in MDS/MPN.

Key Points

  • To evaluate clinicopathological features, treatment strategies, and survival outcomes in patients with non-CMML MDS/MPN.
  • Conducted chart reviews using electronic records from 17 UK centres
  • Classified MDS/MPN according to WHO2022 classification
  • Used descriptive statistics for demographics, treatment strategies, and clinical outcomes
  • Identified 89 patients with varying MDS/MPN subtypes, median age at diagnosis 74
  • Median overall survival for the cohort was 28.9 months; MDS/MPN-N had the shortest OS at 11 months
  • 29% had karyotypic abnormalities; mutations ASXL1 and RUNX1 were linked to worse progression-free survival.

Cite This Study

Alabdulkarim et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d20ahttps://doi.org/10.1182/blood-2025-7365
View Full Paper
Ask AI
Bookmark
Share